Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| STANDARD BIOTOOLS INC.FLDM · Entity 6116 | Director | March 10, 2020 | March 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
STANDARD BIOTOOLS INC.
Report date March 10, 2020 · Filed March 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 161,109 |
Ending reported balance
After 2020-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-10 · Purchase · Acquired 10,000 · Balance 151,109 F1: The range of prices for the transactions reported is between $2.755 and $2.78 per share. $2.7738 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price. Row 2 · 2020-03-11 · Purchase · Acquired 10,000 · Balance 161,109 F2: The range of prices for the transactions reported is between $2.645 and $2.67 per share. $2.6545 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectColella Family Partners, L.P | 5,561 |
Reported balance
Holding disclosure · report date 2020-03-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,561 F3: The shares are held by Colella Family Partners, L.P., of which the Reporting Person is the General Partner. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectColella Family Exempt Marital Deduction Trust dated 9/21/1992 | 69,272 |
Reported balance
Holding disclosure · report date 2020-03-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 69,272 |
| Common StockSEC Table I · non-derivative | IndirectColella Family Non-Exempt Marital Deduction Trust dated 9/21/1992 | 3,326 |
Reported balance
Holding disclosure · report date 2020-03-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,326 |
Filing footnotes · ownership attribution and instrument terms
F1: The range of prices for the transactions reported is between $2.755 and $2.78 per share. $2.7738 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price.
F2: The range of prices for the transactions reported is between $2.645 and $2.67 per share. $2.6545 represents the weighted average purchase price per share. The Reporting Person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price.
F3: The shares are held by Colella Family Partners, L.P., of which the Reporting Person is the General Partner. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein, if any.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. F3: 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92. |
| Common StockSEC Table I · non-derivative | IndirectThe Samuel Colella Trust | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. |
| Common StockSEC Table I · non-derivative | IndirectBy the Colella Family Trust | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 72,035 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F3: 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92. F4: The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy the Colella Family Exempt Marital Deduction Trust | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F5: The shares are held by the Colella Family Exempt Marital Deduction Trust Dated 9/21/1992 ("Colella Exempt Trust"). The Reporting Person is a trustee and beneficiary of the Colella Exempt Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital III L.P. | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 994,129 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F6: The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Side Fund III | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 5,871 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F7: The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Development Fund III, LLC | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 388,683 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F8: The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Colella Partners | 0 |
Reported balance
After 2021-11-19 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2021-11-19 · Disposition to issuer · Disposed 943 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F9: Shares held by Colella Partners. The Reporting Person is the general partner of Colella Partners. |
| Common StockSEC Table I · non-derivative | IndirectBy Colella Partners II | 0 |
Reported balance
After 2021-11-19 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2021-11-19 · Disposition to issuer · Disposed 19,653 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F10: Shares held by Colella Partners II. The Reporting Person is the general partner of Colella Partners II. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 0 |
Reported balance
After 2021-11-19 transaction · row 10
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 10 · 2021-11-19 · Disposition to issuer · Disposed 250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.61 · Expires 2024-03-02 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.85 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92.
F4: The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust.
F5: The shares are held by the Colella Family Exempt Marital Deduction Trust Dated 9/21/1992 ("Colella Exempt Trust"). The Reporting Person is a trustee and beneficiary of the Colella Exempt Trust.
F6: The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
F7: The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
F8: The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
F9: Shares held by Colella Partners. The Reporting Person is the general partner of Colella Partners.
F10: Shares held by Colella Partners II. The Reporting Person is the general partner of Colella Partners II.
F11: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2018 Filed Jun 21, 2018 16:14 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $28.14 | $0.00 |
DisclosureSEC source: 0001209191-18-038934 · doc4.xml · derivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| May 31, 2018 Filed Jun 2, 2018 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 10,600 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001162194-18-000076 · wf-form4_152790093026108.xml · derivative · entry 9 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2028-05-31 F6 · derivative.exercise_date: 1/12th of the shares subject to the Option will vest monthly, subject to continued service as a director, such that the Option will be fully vested on May 31, 2019. Read SEC document |
| May 31, 2018 Filed Jun 2, 2018 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 6,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000076 · wf-form4_152790093026108.xml · nonDerivative · entry 3 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,023 F1 · security: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · shares: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of (i) one day prior to the date of the next annual meeting of the stockholders of the Company or (ii) May 31, 2019, in each case subject to recipient's continued service as a director through the applicable vest date. Read SEC document |
| May 30, 2018 Filed Jun 2, 2018 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000076 · wf-form4_152790093026108.xml · derivative · entry 8 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F5 · derivative.exercise_date: On September 13, 2017, the Reporting Person was granted Restricted Stock Units, vesting fully on the earlier to occur of: (i) one day prior to the date of the next annual meeting of the stockholders of the Company; or (ii) August 1, 2018, subject to continued service as a director through the vesting date. F5 · derivative.expiration_date: On September 13, 2017, the Reporting Person was granted Restricted Stock Units, vesting fully on the earlier to occur of: (i) one day prior to the date of the next annual meeting of the stockholders of the Company; or (ii) August 1, 2018, subject to continued service as a director through the vesting date. Read SEC document |
| May 30, 2018 Filed Jun 2, 2018 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000076 · wf-form4_152790093026108.xml · derivative · entry 7 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F4 · derivative.exercise_date: On August 1, 2017, the Reporting Person was granted Restricted Stock Units, vesting fully on the earlier to occur of: (i) one day prior to the date of the next annual meeting of the stockholders of the Company; or (ii) August 1, 2018, subject to continued service as a director through the vesting date. F4 · derivative.expiration_date: On August 1, 2017, the Reporting Person was granted Restricted Stock Units, vesting fully on the earlier to occur of: (i) one day prior to the date of the next annual meeting of the stockholders of the Company; or (ii) August 1, 2018, subject to continued service as a director through the vesting date. Read SEC document |
| May 30, 2018 Filed Jun 2, 2018 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000076 · wf-form4_152790093026108.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2018 Filed Jun 2, 2018 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000076 · wf-form4_152790093026108.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 22:53 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 12,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000013 · wf-form4_151873519713080.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,923 F1 · shares: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. Subject to the Reporting Person's continued service with the Issuer through each applicable vesting date, twenty-five percent (25%) of the shares underlying the Restricted Stock Units shall vest quarterly on the last day of each quarter during 2018. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:52 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000007 · wf-form4_151501632861387.xml · derivative · entry 6 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,848 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F3 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) vested on December 31, 2017. F3 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) vested on December 31, 2017. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:52 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000007 · wf-form4_151501632861387.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2017 Filed Jan 3, 2018 21:52 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GiftCommon Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000007 · wf-form4_151501632861387.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,245 Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 00:56 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000155 · wf-form4_150699215427384.xml · derivative · entry 5 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,848 Underlying: Common Stock · 7,848 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F3 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017 subject to serving as a director through such date. F3 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017 subject to serving as a director through such date. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 00:56 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 7,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000155 · wf-form4_150699215427384.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 01:07 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001162194-17-000133 · wf-form4_150543763281417.xml · derivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2027-08-01 F3 · derivative.exercise_date: 1/12th of the total number of shares subject to the Option will vest each month after the Vesting Commencement Date, on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that the Option will be fully vested one year following the Vesting Commencement Date, subject to recipient continuing to serve as a director of the Company through each such vesting date. "Vesting Commencement Date" shall mean August 1, 2017. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 01:07 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000133 · wf-form4_150543763281417.xml · derivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of (i) one day prior to the date of the next annual meeting of the stockholders of the Company or (ii) August 1, 2018, in each case subject to recipient's continued service as a director through the applicable vest date. F2 · derivative.expiration_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of (i) one day prior to the date of the next annual meeting of the stockholders of the Company or (ii) August 1, 2018, in each case subject to recipient's continued service as a director through the applicable vest date. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 00:30 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | PurchaseCommon Stock | 35,895 | $2.77 | $99,357.36 |
DisclosureSEC source: 0001162194-17-000095 · wf-form4_150223861967481.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Colella Family Exempt Marital Deduction Trust dated 9/21/1992 Disclosed balance after: 53,395 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.55 to $3.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 20:43 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 15,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000108 · wf-form4_150239779812662.xml · derivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,696 Underlying: Common Stock · 15,696 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units will vest on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017, in each case subject to serving as a director through such date. F2 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units will vest on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017, in each case subject to serving as a director through such date. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 00:39 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001162194-17-000088 · wf-form4_150172073507202.xml · derivative · entry 7 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-01 F4 · derivative.exercise_date: 1/12th of the shares subject to the Option will vest monthly, subject to continued service as a director, such that the Option will be fully vested on August 1, 2018. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 00:39 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000088 · wf-form4_150172073507202.xml · derivative · entry 6 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F3 · derivative.exercise_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of one day prior to the date of the next annual meeting of the stockholders of the Company or August 1, 2018, subject to continued service as a director through the vesting date. F3 · derivative.expiration_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of one day prior to the date of the next annual meeting of the stockholders of the Company or August 1, 2018, subject to continued service as a director through the vesting date. Read SEC document |
| July 31, 2017 Filed Aug 3, 2017 00:39 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000088 · wf-form4_150172073507202.xml · derivative · entry 5 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. Read SEC document |
| July 31, 2017 Filed Aug 3, 2017 00:39 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000088 · wf-form4_150172073507202.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jul 27, 2017 09:37 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-17-046389 · doc4.xml · derivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:49 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 5,000 | $17.01 | $85,047.50 |
DisclosureSEC source: 0001209191-17-038222 · doc4.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Colella Family Exempt Marital Deduction Trust Disclosed balance after: 5,000 F1 · price: The weighted average purchase price for the transaction reported was $17.0095, and the range of prices were between $16.98 and $17.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: The shares are held by the Colella Family Exempt Marital Deduction Trust Dated 9/21/1992 ("Colella Exempt Trust"). The Reporting Person is a trustee and beneficiary of the Colella Exempt Trust. Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:24 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | OtherCommon Stock | 3,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000060 · wf-form4_149583385843039.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Colella Family Non-Exempt Marital Deduction Trust dated 9/21/1992 Disclosed balance after: 3,326 Read SEC document |
| May 24, 2017 Filed May 26, 2017 21:24 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | OtherCommon Stock | 3,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000060 · wf-form4_149583385843039.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,197 Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:08 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | PurchaseCommon Stock | 7,500 | $5.93 | $44,437.50 |
DisclosureSEC source: 0001162194-17-000044 · wf-form4_149454048867838.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Colella Family Exempt Marital Deduction Trust dated 9/21/1992 Disclosed balance after: 17,500 Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 18:24 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | PurchaseCommon Stock | 10,000 | $5.00 | $49,973.00 |
DisclosureSEC source: 0001628280-17-002596 · wf-form4_148960224888190.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Colella Family Exempt Marital Deduction Trust dated 9/21/1992 Disclosed balance after: 10,000 F1 · shares: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $4.930 to $5.030, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $4.930 to $5.030, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| December 20, 2016 Filed Dec 21, 2016 19:10 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GiftCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-16-000264 · wf-form4_148234740846206.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,523 Read SEC document |
| December 14, 2016 Filed Dec 15, 2016 00:05 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | PurchaseCommon Stock | 5,000 | $7.39 | $36,935.00 |
DisclosureSEC source: 0001162194-16-000262 · wf-form4_148176029311514.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,123 F2 · shares: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $7.36 to $7.42, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $7.36 to $7.42, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 14:40 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 10,000 | $16.38 | $163,807.00 |
DisclosureSEC source: 0001209191-16-153270 · doc4.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Colella Family Trust Disclosed balance after: 43,333 F1 · price: The weighted average purchase price for the transaction reported was $16.3807, and the range of prices were between $16.15 and $16.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 21:18 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | PurchaseCommon Stock | 20,000 | $6.32 | $126,470.00 |
DisclosureSEC source: 0001162194-16-000259 · wf-form4_148071347603101.xml · nonDerivative · entry 3 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,123 F2 · shares: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $6.17 to $6.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $6.17 to $6.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 18:40 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 33,333 | $18.00 | $599,994.00 |
DisclosureSEC source: 0001209191-16-151796 · doc4.xml · nonDerivative · entry 1 COLELLA SAMUEL D · CIK 0001201580 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Colella Family Trust Disclosed balance after: 33,333 F1 · ownership.nature: The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust. Read SEC document |
| March 15, 2016 Filed Dec 2, 2016 21:18 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GiftCommon Stock | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-16-000259 · wf-form4_148071347603101.xml · nonDerivative · entry 2 COLELLA SAMUEL D · CIK 0001201580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,123 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.